Folie 1 - Translumina

More documents

Recommendations

Info

Study Flow Chart 1007 pts randomized Cypher 335 pts Dual-DES 333 pts Endeavor 339 pts 61 no FU angiogram - 1 uTLR
Data are percentage or mean ± standard deviation; Percentages may not total 100 due to rounding Baseline Clinical Characteristics Cypher (n=335) Dual-DES (n=333) Endeavor (n=339) Age, years 67±11 67±11 67±11 Women 23 23 25 Arterial hypertension 64 65 68 Diabetes 27 29 26 Current smoker 17 20 18 Hypercholesterolemia 69 63 66 History of MI 30 25 26 History of CABG 8 10 9
Page 1 and 2: A Polymer-Free Dual Drug-Eluting St
Page 3 and 4: Background Long-term polymer residu
Page 5 and 6: Background Previous experience with
Page 7 and 8: Background Probucol is a potent lip
Page 9 and 10: Inclusion Criteria ‣ “De novo
Page 11 and 12: Study DES Types • Probucol+rapamy
Page 13: Statistical Analysis Pre-specified
Page 17 and 18: Data are percentage; percentages ma
Page 19 and 20: Primary Endpoint: binary angiograph
Page 21 and 22: QCA Measurements at FU Cypher (n=34
Page 23 and 24: Clinical Follow-Up at 1 year Incide
Page 25 and 26: Conclusions (2) ‣ The efficacy of

Folie 1 - Translumina

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?